News

Vigorous physical activity may reduce the risk of non-communicable diseases, including rheumatoid arthritis and gout.

There were no negative safety signals in postnatal outcomes of exposed children in terms of growth, psychomotor development, and the risk of allergy, atopy, or infectious complications.

Patients with RVO in a nationwide cohort in Denmark had an increased risk to develop overall, ischemic and non-ischemic CVD compared to non-RVO control patients.

In honor of World Sickle Cell Day, Dr. Titi Fasipe shared a comprehensive overview of the current status of gene therapy and the techniques being used for sickle cell disease treatment.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 19, 2022.

A deep learning system provided accurate predictions of occurrence and severity of ROP ≤45 weeks’ PMA based on retinal photographs at first screening.

Dr. Cohen details the latest study from Yale, which indicated that women from lichen sclerosus had increased risk of developing depression and anxiety.

Data from an analysis of the National Inpatient Sample provides insight into the risk of pregnancy complications among women with systemic lupus erythematosus compared to their counterparts without systemic lupus erythematosus in the US over a decade-long period.

New research from the UK suggests educational tools for caregivers are in use and beneficial, but none are universally applied.

The survey identified long-term health complications of sickle cell disease as a primary concern among patients and providers and overall understanding of the disease needs more educational support.

The prevalence rate of VTE was 2% among a large population of SCD patients in Nigeria.

There is not much known on the link between sickle cell disease and romantic relationships, particularly from the male perspective.

Dr. Temeia Martin talks about how her team identified the transition period as a major obstacle for patients with sickle cell disease and what her task force has implemented as a solution.

The FDA amended the EUA to include the use of Moderna in individuals 6 months through 17 years of age and Pfizer in those 6 months through 4 years of age.

The approval represents the first and only specific interleukin-23 (IL-23) inhibitor for this patient population.

An increased risk of obesity and decreased risk of abnormal weight loss was also observed in patients born to mothers with sickle cell disease.

With World Sickle Cell Day approaching, Dr. Titi Fasipe reflects on the developments within the field, such as the continued conversation of disparities and the increased comfort level with new therapies.

“The COVID-19 pandemic causes concern among patients with ARD due to increased risk of infection and heightened isolation from social distancing,” investigators explained.

In the Archway trial, 93.2% of patients preferred treatment with ranibizumab delivered via the PDS compared to only 1.3% of patients who preferred intravitreal injections.

Several prominent dermatologists sound off on the implications of this decision, JAK inhibitors, and how this approval will aid providers in redefining alopecia areata as an autoimmune disorder rather than simply a cosmetic condition.

Azathioprine and 6-mercaptopurine therapeutic drug monitoring informed a management change in 61.9% of the patients with IBD.

New research suggests patients with psoriatic arthritis were at 8 times greater risk of sexual dysfunction and patients with rheumatoid arthritis were at 10 times greater risk when compared to their counterparts without either rheumatic disease.

Investigators confirmed olanzapine and samidorphan (LYBALVI) resulted in statistically significant less weight gain compared to patients with schizophrenia between 16-39 years treated with olanzapine.

Investigators suggested that antipruritic therapies be offered to patients with psoriasis, as most psoriasis therapies did not result in any improvements.

Acute hepatitis of unknown etiology is not reportable in the US, making it difficult to understand whether recent levels are now reaching historic levels.

Egeberg and colleagues suggested that future research could study why physicians would choose to increase dosing – which as the study suggested, influenced cost- rather than switching treatments.

Women show significantly lower risk of first, recurrent life-threatening VTA events than men, while it is more pronounced in patients with NICM.

The study, which assessed data from the JUVE-BASIS trial, suggests baricitinib significantly reduced both the time to and frequency of flares in patients with JIA when compared with placebo.

Dr. Amy Licis details the signs and symptoms of restless leg syndrome and how to identify it from other causes of sleep issues.

Rivaroxaban monotherapy was associated with a 38% lower risk of total cardiovascular and bleeding events.